Related Experiment Videos
Amyloidosis: diagnosis and management
Morie A Gertz1, Martha Q Lacy, Angela Dispenzieri
1Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. gertm@mayo.edu
Clinical Lymphoma & Myeloma
|December 16, 2005
Summary
Amyloidosis is a rare plasma cell disorder with vague symptoms, making diagnosis challenging. Advances include serum free light chain assays and new therapies like chemotherapy and thalidomide.
Area of Science:
- Hematology
- Oncology
- Nephrology
Background:
- Amyloidosis is a rare plasma cell disorder with an incidence of 8 in 1,000,000.
- Symptoms are often vague, including dyspnea, edema, and fatigue, complicating diagnosis.
- Clinical presentations range from nephrotic syndrome to cardiomyopathy and neuropathy.
Purpose of the Study:
- To review the diagnostic challenges and recent therapeutic advancements in amyloidosis.
- To highlight the role of serum immunoglobulin free light chain assays in classification and monitoring.
- To discuss the significance of cardiac biomarkers and novel treatment strategies.
Main Methods:
- Review of clinical presentations and diagnostic workup for amyloidosis.
- Evaluation of the utility of serum immunoglobulin free light chain assays.
- Assessment of emerging therapies, including high-dose chemotherapy and thalidomide.
Main Results:
- Serum free light chain assay aids in classifying amyloidosis and monitoring treatment.
- Cardiac biomarkers are increasingly recognized for outcome assessment.
- Recent therapies show promise in managing this complex disorder.
Conclusions:
- Amyloidosis diagnosis requires a high index of suspicion due to nonspecific symptoms.
- Advancements in diagnostics and therapeutics are improving patient outcomes.
- Multidisciplinary approaches are crucial for effective amyloidosis management.